However, in order to test the therapeutic benefit of XOR inhibition with febuxostat we deliberately chose an approach where confounding factors of pathogen specificity (e.g., gram positive or negative bacteria) and variability in infection seen in other models, that is,. Here, XDH is linked to infection.